Asia Pacific Lab Automation Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Equipment and Software), Equipment (Automated Workstations, Liquid Handling Systems, Robotic Systems, Micr

The Asia Pacific Lab Automation Market is projected to grow significantly, reaching an estimated US$ 1,509.0 million by 2031, up from US$ 945.0 million in 2024, reflecting a compound annual growth rate (CAGR) of 7.1% from 2025 to 2031. This growth is driven by rapid advancements in precision medicine and biotechnology, prompting laboratories in the region to adopt automation technologies to improve efficiency, scalability, and data accuracy.

In a strategic move to address these evolving laboratory needs, MGI Tech Co., Ltd., a prominent player in life sciences and healthcare innovation, announced on January 30, 2024, an expansion of its automation product portfolio. This new offering encompasses a comprehensive range of automation solutions, from sample pretreatment and preparation to integrated testing, leveraging MGI's extensive expertise in genetic sequencing and multi-omics. These advanced automation solutions are designed to enhance laboratory throughput, consistency, and scalability, catering to a variety of applications, including clinical diagnostics and scientific research. MGI's commitment to improving data-driven workflows in complex life science environments positions it well to meet the increasing demands of regional laboratories and research institutions.

The Asia Pacific Lab Automation Market is segmented by type into Equipment and Software, with Equipment holding the largest market share in 2024. Within the Equipment category, Automated Workstations, Liquid Handling Systems, Robotic Systems, Microplate Readers, and Automated Storage and Retrieval Systems (ASRS) are key segments, with Automated Workstations leading the market. In terms of application, Clinical Diagnostics is the largest segment, followed by Drug Discovery, Proteomics Solutions, and Genomics Solutions. The end-user segmentation includes Hospitals and Diagnostic Centers, Pharmaceutical Companies, Contract Research Organizations (CROs), and Educational and Research Institutions, with Hospitals and Diagnostic Centers dominating the market share in 2024.

The demand for personalized medicine, which relies on genomic, proteomic, and metabolomic data, is a significant driver for lab automation. This approach necessitates the processing and analysis of large volumes of biological samples with high accuracy and speed, capabilities that automated laboratory systems provide. Automation technologies facilitate high-throughput sample preparation, nucleic acid extraction, and next-generation sequencing (NGS), thereby minimizing human error and variability. As the need for custom therapeutics grows, particularly in oncology, rare diseases, and pharmacogenomics, laboratories are under pressure to scale operations while maintaining data quality and compliance. Automation offers a robust solution, enabling research and clinical laboratories to optimize efficiency and resource utilization.

Moreover, precision diagnostics are transforming early disease detection, treatment selection, and monitoring, further amplifying the demand for advanced lab automation. Diagnostic platforms that integrate molecular and genetic testing into routine healthcare workflows require rapid and consistent processing of patient samples, which manual processes can no longer sustain at scale. Automated solutions not only accelerate diagnostic turnaround times but also enhance traceability and standardization, which are critical for meeting regulatory requirements and ensuring clinical accuracy. As wearable health devices and digital biomarkers generate increasingly complex datasets, laboratories must adopt integrated, data-driven automation systems to analyze and act on this information in real time. The convergence of personalized healthcare, digital health, and laboratory automation is expected to create lucrative opportunities for the market in the coming years. Companies that provide scalable, interoperable, and AI-enabled automation solutions are well-positioned to capitalize on this rapidly expanding segment, shaping the future of precision medicine and laboratory innovation.

Geographically, the Asia Pacific Lab Automation Market is segmented into several countries, including China, Japan, India, Australia, South Korea, and the Rest of APAC. China is anticipated to hold the largest market share in 2024, driven by government initiatives such as Healthy China 2030 and a push for global leadership in genomics and AI. These initiatives are fueling demand for sophisticated, high-throughput laboratory automation systems. Hospitals, public health agencies, and life science companies in China are increasingly integrating automated platforms to manage growing workloads in clinical diagnostics, genomic sequencing, and pharmaceutical research and development. MGI Tech, as a leading domestic innovator, plays a crucial role in this landscape, with its automation solutions being deployed across major institutions and utilized in nationwide health projects. Global companies like Thermo Fisher Scientific, Beckman Coulter, and Roche Diagnostics are also expanding their presence in the region, often through local partnerships or manufacturing facilities. With a large population and an aging demographic, the demand for lab automation in China is on the rise, particularly in Tier 1 and Tier 2 cities.

Key players in the Lab Automation Market include Honeywell International Inc., Siemens AG, Abbott Laboratories, bioMerieux SA, Eppendorf SE, Revvity Inc., Agilent Technologies Inc., Analytik Jena GmbH+Co. KG, Danaher Corp, and Thermo Fisher Scientific Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market share and deliver innovative products to consumers. Show more